Regencell Investors Face June 23 Deadline in Securities Fraud Lawsuit

Investors who purchased Regencell Bioscience Holdings Limited securities between October 28, 2024, and October 31, 2025, face a June 23, 2026, deadline to seek lead plaintiff status. Rosen Law Firm, which filed the class action, is currently organizing claimants who suffered significant financial losses during the period.

The lawsuit alleges that Regencell officials issued materially false or misleading statements regarding the company's vulnerability to market manipulation. According to the complaint, these omissions concealed significant financial risks, leading to volatility that resulted in damages for shareholders. The litigation asserts that this lack of transparency exposed the company to heightened regulatory scrutiny and reputational harm.

Those interested in serving as lead plaintiff must move the court by the June 23 deadline. While the class has not yet been certified, investors may choose their own counsel or remain absent members of the class. Rosen Law Firm, which highlights its history in securities litigation and high-value settlements, is managing the outreach for this action. Parties seeking further information or wishing to join the proceedings can contact Phillip Kim at the firm via their online portal or telephone.